The Protective Role of GMI, an Immunomodulatory Protein From , on 5-Fluorouracil-Induced Oral and Intestinal Mucositis

Autor: Che-Hsing Li, Jiunn-Liang Ko, Chu-Chyn Ou, Wea-Lung Lin, Cheng-Chieh Yen, Chih-Ting Hsu, Yu-Ping Hsiao

Publikováno v: Integrative Cancer Therapies, Vol 18 (2019)

5-Fluorouracil (5-FU) is used in the treatment of head and neck cancer patients. However, adverse effects experienced such as mucositis and poor appetite may lead to interruption in chemotherapy. The aim of this study is to evaluate the efficacy of G

Externí odkaz: https://doaj.org/article/a9682745f7884ec59bbfe0e374fd6282

Recombinant Aflatoxin-Degrading F420H2-Dependent Reductase from Mycobacterium smegmatis Protects Mammalian Cells from Aflatoxin Toxicity

Autor: Che-Hsing Li, Wei-Yang Li, I-Ning Hsu, Yung-Yu Liao, Chi-Ya Yang, Matthew C. Taylor, Yu-Fan Liu, Wei-Hao Huang, Hsiang-Hua Chang, Ho-Lo Huang, Shao-Chi Lo, Ting-Yu Lin, Wei-Che Sun, Ya-Yi Chuang, Yu-Chieh Yang, Ru-Huei Fu, Rong-Tzong Tsai

Publikováno v: Toxins, Vol 11, Iss 5, p 259 (2019)

Aflatoxins are carcinogenic secondary metabolites of fungi that contaminate many staple crops and foods. Aflatoxin contamination is a worldwide problem, especially in developing countries, posing health hazards, e.g., causing aflatoxicosis and hepato

Externí odkaz: https://doaj.org/article/ace3ea632a564bed9392cfe86689ae66

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma.

Autor: Che-Hsing L; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX.; Program in Immunology & Microbiology, Baylor College of Medicine, Houston, TX., Sharma S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX., Heczey AA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Steffin DHM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Louis CU; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX., Grilley BJ; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Thakkar SG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX., Wu M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Wang T; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.

Publikováno v: Research square [Res Sq] 2024 Apr 11. Date of Electronic Publication: 2024 Apr 11.